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Abstract 
Background: Artemisinin resistance in Plasmodium falciparum manifests as slow parasite clearance but this measure 
is also influenced by host immunity, initial parasite biomass and partner drug efficacy. This study collated data from 
clinical trials of artemisinin derivatives in falciparum malaria with frequent parasite counts to provide reference para-
site clearance estimates stratified by location, treatment and time, to examine host factors affecting parasite clear-
ance, and to assess the relationships between parasite clearance and risk of recrudescence during follow-up.
Methods: Data from 24 studies, conducted from 1996 to 2013, with frequent parasite counts were pooled. Parasite 
clearance half-life (PC1/2) was estimated using the WWARN Parasite Clearance Estimator. Random effects regression 
models accounting for study and site heterogeneity were used to explore factors affecting PC1/2 and risk of recrudes-
cence within areas with reported delayed parasite clearance (western Cambodia, western Thailand after 2000, south-
ern Vietnam, southern Myanmar) and in all other areas where parasite populations are artemisinin sensitive.
Results: PC1/2 was estimated in 6975 patients, 3288 of whom also had treatment outcomes evaluate d during 
28–63 days follow-up, with 93 (2.8 %) PCR-confirmed recrudescences. In areas with artemisinin-sensitive parasites, the 
median PC1/2 following three-day artesunate treatment (4 mg/kg/day) ranged from 1.8 to 3.0 h and the proportion of 
patients with PC1/2 >5 h from 0 to 10 %. Artesunate doses of 4 mg/kg/day decreased PC1/2 by 8.1 % (95 % CI 3.2–12.6) 
compared to 2 mg/kg/day, except in populations with delayed parasite clearance. PC1/2 was longer in children and in 
patients with fever or anaemia at enrolment. Long PC1/2 (HR = 2.91, 95 % CI 1.95–4.34 for twofold increase, p < 0.001) 
and high initial parasitaemia (HR = 2.23, 95 % CI 1.44–3.45 for tenfold increase, p < 0.001) were associated indepen-
dently with an increased risk of recrudescence. In western Cambodia, the region with the highest prevalence of 
artemisinin resistance, there was no evidence for increasing PC1/2 since 2007.
Conclusions: Several factors affect PC1/2. As substantial heterogeneity in parasite clearance exists between locations, 
early detection of artemisinin resistance requires reference PC1/2 data. Studies with frequent parasite count measure-
ments to characterize PC1/2 should be encouraged. In western Cambodia, where PC1/2 values are longest, there is no 
evidence for recent emergence of higher levels of artemisinin resistance.
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Background
Parasite clearance is a robust measure of the efficacy of 
anti-malarial drugs, which has been used particularly to 
measure the pharmacodynamic effects of artemisinin 
derivatives [1]. Initial studies conducted in patients with 
severe malaria employed frequent parasite counting to 
characterize clearance profiles, and these demonstrated 
that artemisinin derivatives cleared parasitaemia more 
rapidly than quinine [2]. More recently, frequent para-
site counting has been used to characterize artemisinin 
susceptibility in vivo [3], and to validate molecular mark-
ers [4, 5] and in vitro assays for detection of artemisinin 
resistance [6]. Parasite clearance following artemisinin 
treatment is influenced by a number of factors other than 
parasite susceptibility, including host immunity, initial 
parasite biomass and partner drug efficacy. It is therefore 
essential to control for such potential confounding factors 
in order to identify temporal changes in parasite clearance 
resulting from reduced anti-malarial drug susceptibility.
The WorldWide Antimalarial Resistance Network 
(WWARN) Parasite Clearance Estimator (PCE) [7] 
was developed to automate and standardize analysis of 
frequent parasite count data. This tool is freely avail-
able online [8] and provides an automated report for each 
patient. The derived measure, parasite clearance half-life 
(PC1/2), generated by the PCE reflects the extent to which 
ring-stage parasites are killed and removed from the cir-
culation, and is currently considered the most reliable 
measure of parasitological responses to treatment with 
artemisinin or its derivatives [5, 9–16]. This standardized 
approach to PC1/2 measurement allows comparison in 
space and time of artemisinin resistance, which manifests 
as a slow parasite clearance rate in patients. Within the 
WWARN framework, investigators who obtained frequent 
parasite count data have joined several study groups [17] 
to evaluate this metric. This pooled analysis presents refer-
ence parasite clearance estimates stratified by geographic 
location, treatment and study population, and explores 
the relationship between parasite clearance measures and 
the risk of recrudescent infection (treatment failure). The 
effects of different sampling strategies on clearance esti-
mates have been published separately [18].
Methods
Data acquisition
Any study involving patients with uncomplicated falci-
parum malaria, treated with either artemisinin combi-
nation therapy (ACT) or oral artesunate monotherapy, 
in which peripheral parasitaemia was measured at least 
twice daily in the first 3 days after starting treatment, was 
eligible for inclusion in this pooled analysis. In addition, 
the minimum data required were enrolment date, patient 
age, drug treatment, study location and characteristics, 
and details of the parasite counting method. Studies with 
frequent parasite counts were identified using literature 
reviews and existing collaborations within WWARN. 
Principal investigators were subsequently approached 
to participate in this study group [19]. The datasets 
uploaded to the WWARN repository were standardized 
using the WWARN Data Management and Statistical 
Analysis Plans for clinical data [20] and pooled into a sin-
gle database of quality-assured individual patient data.
Parasite inclusion criteria, counting methods and blood 
sampling schedules were different among studies; for a 
detailed description see Additional file 1: Table S1.
Statistical analysis
Definitions
As a measure of transmission intensity, malaria endemic-
ity estimates were obtained for study sites and year from 
the Malaria Atlas Project [21]. Anaemia was defined 
according to WHO guidelines [22], (i.e., haemoglobin 
concentration cut-offs for moderate anaemia were 10 g/dL 
in children <5 years of age and 11 g/dL in older patients, 
and for severe anaemia were 7 and 8 g/dL, respectively). 
For studies where haematocrit only was measured, the 
following relationship was used to estimate haemoglo-
bin: haematocrit (%)  =  5.62  +  2.60  ×  haemoglobin (g/
dL) [23]. Nutritional status of children aged <5 years was 
assessed by the weight-for-age indicator using the igrowup 
package developed by the WHO [24].
Analysis of parasite counts
PC1/2 was estimated only for patients with sufficient par-
asite counts defined as sampling at least 12-h in the first 
48 h (a maximum of a 16-h gap between any two meas-
urements, as a 2-h window on each side was allowed) and 
at least 24-h sampling (maximum 28-h gap) after 48  h 
until parasite clearance [18]. The following deviations 
from this rule were accepted as they were deemed not to 
have substantial effects on the PC1/2 estimate [18]: sam-
pling was not performed until parasite clearance but the 
last recorded parasitaemia was <100 or <1000 parasites/
µL with at least five positive parasite counts available; 
a longer gap was observed between a set of measure-
ments but there were at least two positive parasite counts 
directly after the gap, or a zero count was recorded after 
the gap and the last recorded parasitaemia before the gap 
was either <100 or <1000/µL and at least five positive par-
asite count measurements were available before the gap.
PC1/2 was calculated by the PCE [7] for each patient 
(variable called slope_half_life in the output files), based 
on the linear segment of the decline in the log-trans-
formed parasitaemia-time profile. A lag-phase (an ini-
tial, flat part of the parasitaemia-time profile which 
precedes the log-linear decline) and a tail (a levelling 
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out in the parasitaemia-time profile which follows the 
log-linear decline), if present, are identified by the PCE 
automatically.
Reliability of PC1/2 estimates was assessed by (a) the 
standard deviation of residuals from the final linear 
model used to estimate PC1/2; (b) the duration of the 
lag phase (as a long lag phase is very unlikely if an arte-
misinin derivative is given and absorption is adequate); 
(c) the number of positive parasite counts used in the 
estimation; (d) pseudo-R2 statistics; and, (e) the width of 
the 95 % confidence interval around the PC1/2.
Pseudo-R2 is a measure of goodness of fit of the final 
model and is provided by the PCE tool. Low values of 
pseudo-R2 indicate that the predicted values from the 
polynomial model are far from the measured parasitae-
mias. Pseudo-R2 is calculated from the fitted values of the 
final linear model used to estimate the PC1/2 (after exclu-
sion of the lag phase and tail) and the observed log-para-
sitaemias, excluding zero counts.
Parasite clearance and clinical covariates
Factors affecting PC1/2 were investigated in the ran-
dom effects regression model (to account for study site 
heterogeneity) with PC1/2 being modelled after log 
transformation. Separate analyses were performed in 
artemisinin-resistant and artemisinin-sensitive areas. The 
resistant areas were defined as locations in which delayed 
parasite clearance had been reported previously [3, 9–11, 
14–16, 25–28] (i.e., western Cambodia, western Thailand 
after 2000, southern Vietnam, southern Myanmar), while 
the sensitive areas were defined as all other locations.
In studies which randomized treatment arms to 2 and 
4 mg/kg/day artesunate doses, meta-analysis of the dif-
ferences in mean log-transformed PC1/2 between treat-
ment arms was performed using a fixed effects model 
using the inverse variance method. Heterogeneity was 
evaluated by I2 [29].
Analysis of treatment outcome
The risk of recrudescence was assessed by survival anal-
ysis using WHO definitions of therapeutic efficacy out-
come [30]. Patients with no PCR results were excluded 
from the treatment outcome analysis. Cox regression 
model with random effects in the form of frailty param-
eters were used to adjust for study site effects [31]. The 
proportional hazard assumption was tested based on 
Schoenfeld residuals [32]. PC1/2, presence of a lag phase, 
duration of lag phase and presence of a tail were evalu-
ated as possible predictors of outcome, together with all 
other baseline clinical and treatment characteristics.
Covariates for the final regression models (for treat-
ment outcome and PC1/2) were selected on the basis of 
the likelihood ratio test and examination of residuals. 
Relationship between the independent variable and 
continuous covariates such as age and parasitaemia was 
examined using fractional polynomials. All statistical 
analyses were performed using Stata 13.0.
Results
Data summary
Data from 9318 patients enrolled from 1996 to 2013 in 
24 studies [3, 9–15, 26, 33–43] (Additional file  2: Table 
S2; Fig. 1) conducted at 61 study sites in 46 distinct loca-
tions (Fig. 2) in 18 countries (Bangladesh, Benin, Burkina 
Faso, Cambodia, Democratic Republic of Congo, Gabon, 
Ghana, India, Kenya, Laos, Mali, Mozambique, Myan-
mar, Nigeria, Tanzania, Thailand, Uganda, Vietnam), 
were available for analysis.
Among hyperparasitaemic patients (Study ID 1), 882 of 
3393 (26 %) patients were excluded from analysis because 
of one or more of the following: severe malaria (n = 108), 
slow parasite clearance and administration of rescue 
treatment with intravenous or intramuscular artesunate 
(n = 642), blood transfusion before clearance of parasites 
(n = 215), or incomplete treatment information (n = 19). 
Table  1 shows the demographic and clinical parameters 
of patients with uncomplicated Plasmodium falciparum 
malaria who were included in this analysis.
Patients were treated with (a) artesunate (AS) alone 
(n = 842); (b) AS alone in the first 3 days or longer fol-
lowed by a standard ACT: artemether-lumefantrine (AL); 
artesunate-amodiaquine (ASAQ); artesunate-meflo-
quine (ASMQ); or dihydroartemisinin-piperaquine (DP) 
(n = 2751); (c) AL (n = 2217); (d) DP (n = 55); (e) ASMQ, 
with the first dose of MQ administered at a median 
(range) of 46 (0–71) hours (n = 1343); or (f ) artesunate-
chlorproguanil-dapsone (n =  914). There were also 341 
hyperparasitaemic patients studied in Thailand (Study ID 
1) who received AS together with either doxycycline or 
clindamycin.
The target daily dose of AS varied between 2 (n = 862, 
24 %), 4 (n = 2,544, 71 %), 6 (n = 119, 3 %), and 8 (n = 66, 
2  %) mg/kg, with patients in Cambodia receiving the 
higher doses of 6 or 8 mg/kg in one study. In two stud-
ies the initial dose of AS was higher than on subsequent 
days: in hyperparasitaemic patients in Thailand (Study 
ID 1: 4  mg/kg followed by 2  mg/kg, n  =  2509) and in 
patients in Mali (Study ID 14: 6 or 4 mg/kg followed by 
2 mg/kg, n = 100). Seven studies (Study IDs: 2, 6, 10, 11, 
13, 17, 24) at 14 locations randomized 1242 patients to 
either 2 mg/kg or 4 mg/kg daily doses of AS, alone or in 
combination with an ACT given at 72 h.
Estimates of parasite clearance
Among 8536 patients, 6975 (82 %) had sufficient parasite 
counts taken for PCE estimation of PC1/2. The majority 
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Fig. 1 Study profile
Fig. 2 Map of study sites included in the parasite clearance data analysis
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of the excluded patients came from three studies with 
variable sampling schemes (59 %, Study IDs 4, 20, 21) and 
from the study with hyperparasitaemic patients (36  %, 
Study ID 1), which for 10 years routinely recorded parasi-
taemia every 6 h until clearance.
Only two positive parasite counts were used to estimate 
PC1/2 in 878 patients, either because only two positive 
measurements were available (n = 844) or measurements 
were excluded as being part of the lag or tail phases 
(n = 34). For these profiles with only two positive para-
site counts available, the PCE replaces the first zero count 
with the detection limit [7] and the resulting PC1/2 esti-
mate clearly overestimates the true PC1/2. However, the 
estimated PC1/2 was still considered informative as 25 % 
(214/844) of these profiles had estimated values  <2  h 
and 73  % (618/844) had estimated values  <3  h, indicat-
ing that parasite clearance in these patients was rapid 
and thus provided no evidence for artemisinin resist-
ance. Of the remaining patients, 73 % (165/226) with an 
estimated PC1/2 >3 h had an initial parasitaemia <10,000 
parasites/µL and 77  % (175/226) had parasite counts 
measured using one of the twice-daily schemes. For 21 % 
(1489/6975) of profiles, a non-zero lag phase was esti-
mated with median (range) duration of 6 (1.5–60) hours, 
with 6 % (90/1489) having a lag phase duration >12 h.
The median (range) goodness of fit statistic, pseudo-
R2, was 0.938 (−198 to 0.999), with 89 % (6197/6975) of 
profiles having a pseudo-R2  >0.8. Only 0.9  % (65/6975) 
of profiles had a negative pseudo-R2, indicating that the 
model was not a good representation of the data.
The 95 % confidence interval (CI) for the estimated PC1/2 
was wide for 11 % (740/6975) of profiles; the 95 % CI either 
included negative values or the upper limit was greater than 
twice the PC1/2 estimate. Of these, 70 % (519/740) were for 
patients with only two positive parasite counts available.
For the distribution of PC1/2 by location, treatment 
and study year see Additional file 3. See Additional file 4: 
Table S3 for summaries of PC1/2 and other parasitological 
measures by location and treatment and Additional file 5: 
Table S4 for proportion of profiles with PC1/2 longer than 
3, 4, 5 and 6 h.
Areas with slow parasite clearance
Delayed parasite clearance was observed at sites in Cam-
bodia, Thailand, Myanmar, and Vietnam. For all treat-
ments and locations, the longest PC1/2 were observed in 
three western Cambodian sites: Pailin, Tasanh and Pursat 
where data from 2007 to 2012 were available; study median 
PC1/2 ranged from 5.6 to 6.7  h, and the proportion of 
PC1/2 >5 h ranged from 61 to 80 %. Importantly, no signifi-
cant trend of increasing PC1/2 was observed at these sites 
over that time interval. At the two other Cambodian sites, 
Ratanakiri and Preah Vihear, parasite clearance was signifi-
cantly faster (p < 0.001; median PC1/2 of 3.0 and 3.8 h, and 
proportion of PC1/2 >5 h of 4 and 22 %, respectively) and 
also different between these two sites (p = 0.011).
In contrast, a disproportionate increase in PC1/2 was 
observed in western Thailand after 2003 (p < 0.001, frac-
tional polynomials), with an average increase in PC1/2 of 
7.1 % (95 % CI 5.7–8.6) per year after 2005. The PC1/2 val-
ues (p = 0.247) and changes in PC1/2 over time (p = 0.628) 
were similar in hyperparasitaemic and uncomplicated fal-
ciparum malaria patients from 2008 to 2011 (Additional 
file  3: Figure S2). Overall, the proportion of PC1/2  <3  h 
decreased from 67 % (n = 169) in 2003 to 11 % (n = 75) in 
2012, and the proportion of PC1/2 >5 h increased from 6 to 
55 % during this time period (Additional file 4: Table S4).
Areas with rapid parasite clearance
Among studies in areas with artemisinin-sensitive para-
sites (n = 3208), patients who received AS 2 mg/kg (with 
or without partner drugs) or the standard six-dose AL 
regimen had longer PC1/2 values compared to patients 
who received AS 4 mg/kg (with or without partner drugs) 
by 7.3 % (95 % CI 1.9–12.9, p = 0.007) and 7.4 % (95 % CI 
3.8–11.2, p < 0.001), respectively (Fig. 3). These compari-
sons are adjusted for study site and study design charac-
teristics which affect PC1/2 estimates: (a) patients with 
twice-daily sampling (Study IDs 4, 13, 20, 21) had 16.2 % 
(95 % CI 7.6–25.6) longer PC1/2 compared to those with 
more frequent schedules (p  <  0.001); (b) patients with 
insufficient number of data points to estimate lag phases 
had 31 % (95 % CI 26–37) longer PC1/2 than those with 
sufficient data (p  <  0.001). Since patients with very low 
initial parasitaemias and short PC1/2 are excluded from 
Table 1 Baseline characteristics of patients included in the 
analysis
a Defined according to WHO guidelines [23]. For studies where only haematocrit 
was measured, the following relationship was used to estimate haemoglobin 
concentration: Haematocrit = 5.62 + 2.60 × Haemoglobin [24]
b Defined as axillary temperature >37.5 °C
Parameter Median (range) [n or n/N]
Age (years) 10 (0.1–70) [6970]
Parasitaemia (/µL) 70,336 (1000–2,285,920) [6966]
Temperature (°C) 38.0 (34.1–41.5) [3266]
Haemoglobin (g/dL) 12.4 (2.1–19.9) [1812]
Haematocrit (%) 35.0 (11.3–50) [3251]
Anaemiaa
 None 59 [2359/3966]
 Moderate 36 [1422/3966]
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the analysis because of insufficient data, this creates a 
negative association between the initial parasitaemia and 
PC1/2 (Fig. 4). Mean PC1/2 was estimated to decrease by 
16 % (95 %CI 15–18) per tenfold increase in parasitaemia.
In artemisinin-sensitive areas, profiles with a lag phase 
had 6.4  % (95  % CI 3.6–9.1) shorter PC1/2 compared to 
profiles without a lag phase (p < 0.001, adjusted for all the 
above factors). No association was observed between the 
duration of the lag phase and PC1/2 among 687 patients 
with a non-zero lag phase (p  =  0.220, adjusted for the 
above factors).
Initial parasitaemia
Studies differed in their admission parasitaemia inclusion 
criteria. It was assumed that the log-transformed initial 
parasitaemias followed a truncated normal distribution 
with lower and upper truncation consistent with the 
inclusion criteria. In all but five studies, there was no 
evidence against this assumption of truncated normality 
(p values ranged from 0.17 to 0.98); the exceptions were 
four multi-centre and/or multi-country studies (Study 
IDs 4, 21, 22, 23) and a study with two distinct age groups 
(Study ID 20; young children weighing 12–20  kg and 
older children weighing 20–40 kg). For these five studies, 
there was clear evidence of a multimodal distribution of 
initial parasitaemias.
Parasite clearance and clinical covariates
Areas with rapid parasite clearance
In artemisinin-sensitive areas (all countries in Africa, 
Laos, Bangladesh, Thailand before year 2000, Ratanakiri 
in Cambodia; n = 3208), after adjusting for study design 
factors, patient age and treatment were associated inde-
pendently with PC1/2. Adjusting for age changed the 
treatment effect very little. Patients who received 2 mg/
kg AS or AL had 7.2 % (95 % CI 1.8–12.8) and 7.3 % (3.7–
11.0) longer PC1/2, respectively, compared to patients 
who received 4 mg/kg AS (p  ≤  0.008). Young children 
cleared parasites more slowly than older patients: PC1/2 
was 11.3 % (95 % CI 2.6–20.8, p = 0.010) longer in infants 
aged  <1  year and 9.4  % (95  % CI 3.5–15.7, p  =  0.002) 
longer in children aged 1–4  years compared to older 
patients (Fig.  5a, b). There was no significant difference 
in PC1/2 between children aged 5–14  years and adults 
(p  =  0.129). The relationship between patient age and 
PC1/2 was examined further in the multivariate model 
(Fig.  5c). After adjusting for age and treatment, higher 
parasitaemia remained associated with lower estimates 
of PC1/2 (by a 17 % (95 % CI 15–18) per tenfold increase 
in parasitaemia). Other factors, examined on a subset of 
patients with available data, were independently associ-
ated with longer PC1/2: fever (7.0  %, 95  % CI 3.2–10.8, 
p  <  0.001, n =  1636); severe anaemia (13.5  %, 95  % CI 
6.4–21.1, p  <  0.001, n  =  2043) and moderate anaemia 
defined as haemoglobin level from 7 to 9  g/dL (4.3  %, 
95 % CI 1.0–7.7, p =  0.010, n =  2043). No associations 
between PC1/2 and gametocyte carriage, transmission 
intensity or nutritional status of children were observed. 
A lag phase was detected more frequently in patients 
receiving AL (OR =  2.14, 95  % CI 1.29–3.59 compared 
to other treatments, p  =  0.004), high initial parasitae-
mia (OR = 1.77, 95 % CI 1.28–2.45 per tenfold increase, 
p = 0.001) or fever (OR = 1.63, 95 % CI 1.21–2.21 com-
pared to patients presenting without fever, p  =  0.001). 
Among 1297 patients treated with AL [median (range) 
daily artemether dose 2 (0.9–4) mg/kg], no significant 
association was found between PC1/2 and artemether 
dose. In contrast, none of the patient covariates or treat-


























AS 4mg/kg AS 2mg/kg AL western Cambodia
Fig. 3 Distribution of PC1/2 by treatment group in areas with 
artemisinin-sensitive parasite population. Figure in red shows PC1/2 
values in all western Cambodian sites for comparison
Fig. 4 Relationship between initial parasitaemia and estimated PC1/2 
in patients in areas with artemisinin-sensitive parasite populations. 
Red line shows locally weighted scatterplot smoothing estimator 
(LOWESS)
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Areas with slow parasite clearance
In areas with previously documented slow parasite clear-
ance rates, no significant association between PC1/2 and 
patient age was observed. After adjusting for study design 
factors, admission gametocytaemia was associated with 
an 11.1 % (95 % CI 5.5–16.9, p < 0.001, n = 3574) increase 
in PC1/2, and temperature >37.5 °C was associated with a 
7.3 % (95 % CI 1.3–13.8, p =  0.017, n =  1491) increase 
in PC1/2. The relationship between PC1/2 and initial par-
asitaemia was the opposite of that in the artemisinin-
sensitive population: a tenfold increase in parasitaemia 
was associated with a 5.2 % (95 % CI 0.7–9.9, p = 0.024, 
n = 3574) increase in PC1/2 when adjusted for study site.
Artemisinin dose and PC1/2
Six studies at 15 locations had randomized AS treatment 
arms of 2 and 4 mg/kg. The higher dose was associated 
with an 8.1 % (95 % CI 3.2–12.6, p = 0.001) decrease in 
PC1/2 in sites with geometric mean PC1/2  <4  h (in AS 
2  mg/kg dose arm), whereas there was no significant 
(p = 0.455) difference in PC1/2 in the remaining sites with 
geometric mean PC1/2  ≥4  h. Overall change was esti-
mated as −5.5 % (95 % CI −9.7 to −1.2, p = 0.013) (test 
for heterogeneity between groups, p = 0.031) (Fig. 6).
Treatment outcome
Among 3328 patients with defined outcome, 93 (2.8  %) 
had PCR-confirmed recrudescences by day 63. After 
adjusting for study design factors in a multivariate 
model, longer PC1/2 was associated with an increased 
risk of recrudescence: HR = 2.91, 95 % CI 1.92–4.31, for 
a doubling of PC1/2, p < 0.001). Patients with high initial 
parasitaemia also had a higher risk of recrudescence: 
HR  =  2.23, 95  % CI 1.44–3.46, for a tenfold increase 
in parasitaemia, p  <  0.001. No significant interaction 
between PC1/2 and initial parasitaemia was detected. 
After adjusting for the initial parasitaemia, PC1/2 and 
parasite sensitivity status, the recrudescence rates varied 
Fig. 5 Relationship between patient age and PC1/2 in patients in areas with artemisinin-sensitive parasites. (1) Observed data in Africa (a) and Asia 
(b) with red line showing locally weighted scatter-plot smoothing estimator (LOWESS); only patients with 6-h sampling and enough data points for 
the full Parasite Clearance Estimator model to be fitted are presented; (2) predicted relationship from multivariate model using fractional polynomi-
als (c); adjusted for treatment group, region, initial parasitaemia, presence of lag phase and study design characteristics
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between regimens with different partner drugs or time of 
their administration. Recrudescence rates were signifi-
cantly higher in patients receiving artesunate-chlorpro-
guanil-dapsone than any other ACT (HR = 3.62, 95 %CI 
1.74–7.52, p =  0.001) Recrudescence rates were signifi-
cantly lower in patients receiving AS for 3 days followed 
by a standard ACT at 72  h (HR =  0.28, 95  % CI 0.11–
0.74, p = 0.010) than in all other patients. Other baseline 
covariates, as well as the presence or duration of lag and 
tail phases in the parasite clearance curve, were not asso-
ciated with treatment outcome.
Discussion
The rate at which asexual P. falciparum parasites are 
cleared from the blood following treatment is the best 
measure of the anti-malarial effect of artemisinin and its 
derivatives. This is assessed from the linear component of 
the log-linear decline in parasite densities and is expressed 
conveniently as PC1/2 [1]. Resistance to artemisinins 
results in prolongation of the PC1/2. This pooled analysis 
combines the largest set of data, collected in 24 studies 
over 18  years, from nearly 7000 patients with uncompli-
cated falciparum malaria in whom frequent measurements 
of parasitaemia were made. The reference PC1/2 estimates 
provided for 46 locations across Africa and Asia are essen-
tial comparators for the early recognition of emerging 
resistance, and so will be updated continuously as others 
join the WWARN [44] collaborative effort and provide rel-
evant data sets. An important output of this analysis is that 
there was no evidence for worsening of artemisinin resist-
ance in western Cambodia. There is substantial concern 
that failure to eliminate falciparum malaria in this area, the 
‘cradle of antimalarial drug resistance’, will lead to higher 
levels of artemisinin resistance, rendering ACTs progres-
sively less effective. While further worsening of the degree 
of artemisinin resistance fortunately has not happened, at 
least until 2012, continued monitoring is vital.
This large dataset allowed estimation of the additional 
contributions of patient characteristics and study design 
to parasite clearance estimates, information that is cru-
cial in interpreting and monitoring changes in these 
estimates, and attributing them to true artemisinin 
resistance rather than the effects of partner drugs, study 
design or patient characteristics. The recent discovery 
[4] and validation [15] of the molecular marker kelch13 
in the Greater Mekong area and the development of suit-
able in  vitro sensitivity tests [6, 45] provide important 
information. Data from in vitro ring-stage survival assays 
do reflect artemisinin resistance in vivo, but their use is 
likely to be limited to few resourced laboratories and thus 
unlikely to provide comprehensive surveillance infor-
mation across endemic countries. Mutations in kelch13 
Fig. 6 Meta-analysis of dose effect in randomized studies with artesunate alone in the first 72 h. 1geometric mean of PC1/2 in 2 mg/kg treatment 
arm
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above position 440 correlate with slow parasite clearance 
rates in the Greater Mekong area, but have not yet been 
associated with slow rates elsewhere, and cannot yet sub-
stitute for PC1/2 values as definite measures of clinical 
artemisinin resistance.
Estimation of PC1/2 requires sufficient quality-assured 
serial parasite blood counts for analysis. In this very 
large series, the most common problem encountered 
(13  %) was that only two positive counts were available 
because of rapid parasite clearance and low initial para-
sitaemias. Other problems encountered (10  %) were a 
very long lag phase, large variations in parasite counts 
resulting in poor fits or large confidence intervals around 
the estimate. These were most likely a consequence of 
inaccurate microscopy counts. The initial parasitae-
mia and frequency of sampling had the greatest effects 
on the PC1/2 estimates, which accords with results of a 
previously reported simulation study [18]. Ideally, only 
patients with initial parasitaemia  >10,000 parasites/µL 
should be included in PC1/2 assessments. In patients with 
only two positive parasite counts, estimated PC1/2 should 
be interpreted with caution as it is likely to be overesti-
mated. This is because the lag phase cannot be evaluated 
and the first recorded zero parasitaemia is treated as a 
parasite density at the detection limit (so the worst case 
scenario is assumed). Profiles for which the lag or tail 
phases were identified, and after their exclusion only two 
data points were left for the PC1/2 estimation, should be 
excluded from analysis as they likely represent limitations 
in microscopy-based parasite counting.
A lag phase was detected more frequently in patients 
presenting with fever, possibly because of the association 
of fever with synchronous schizont rupture. The more 
frequent lag phase with AL treatment may result from the 
initial lower dose and slower absorption and conversion 
to DHA of oral artemether compared to oral artesunate 
[46]. Patients with profiles beginning with a lag phase 
may have had more rapid clearance in the log-linear part 
of the parasitaemia-time curve (lower PC1/2); however, 
the difference was rather small (6.4 %, 95 % CI 3.6–9.1). 
This is an artefact of the way the model is fitted—as the 
lag phase is defined only if the initial clearance is slower 
and the ratio of the clearance rates between this initial 
period and the rest of the parasitaemia profile reaches a 
pre-specified cut-off. Some of the observed differences in 
slopes are caused by random variation of the microscopy 
measurement. Excluding this randomly occurring slower 
(but not faster) part of the profile will result in the over-
estimation of PC1/2 in profiles with a detected lag phase. 
This phenomenon was observed in 3–10 % of simulated 
parasite profiles (using previously described methodol-
ogy [18]), from distributions of PC1/2 with mean of two 
to 6 h and standard deviation (log scale) from 0.05 to 0.3.
The treatment, clinical and demographic variables 
studied had modest effects on PC1/2 estimates, all result-
ing in less than 20  % change in PC1/2, and none associ-
ating with an increased risk of PC1/2 being  >5  h in the 
rapid-clearing parasite populations.
In areas with artemisinin-sensitive parasite popula-
tions, parasite clearance was faster in patients receiving 
the 4 mg/kg dose of AS than in those receiving the 2 mg/
kg dose, which was a robust finding confirmed in meta-
analysis performed in a subset of randomized studies as 
well as in a multivariate analysis of studies with either of 
the doses administered. It is therefore expected that there 
will be marked differences between the various currently 
available ACTs, including AL, ASAQ, DHA-PQP and 
ASMQ, depending on the dose of artemisinin deriva-
tive. However, after adjusting for the sampling scheme, 
the proportions of patients with PC1/2 estimates  >5  h 
were not significantly different between treatments in 
this study and ranged from 0 to 10 % for studies with six-
hourly sampling, and from 0 to 7 % after exclusion of pro-
files with pseudo R2 statistic <0.8.
Therapeutic responses in malaria are enhanced by 
immunity [1]. As expected from previous work [47, 48], 
young children had slower parasite clearance rates com-
pared to older patients. However, this was observed only 
in artemisinin-sensitive parasite populations, with most 
data coming from Africa. Resistant parasite populations, 
present only in Southeast Asia, did not demonstrate an 
age effect. The lack of an age effect on PC1/2 could be 
due to one or more of the following factors: lower back-
ground immunity in those patients from low transmis-
sion settings, different age distributions studied with 70 % 
of patients being older than 12 years, nonlinear negative 
age effect on PC1/2 (Fig. 5), or a qualitative pharmacody-
namic difference in that whereas most of the clearance 
of artemisinin-sensitive parasites results from clearance 
of ring-stage parasites in low transmission settings, in 
artemisinin-resistant infections cytoadherence becomes 
a more important contributor to the initial decline in 
parasitaemia (as it is following quinine treatment) [1]. In 
both populations, the presence of fever on admission was 
associated with longer PC1/2. This has also been reported 
in other studies from Kenya [49] and Uganda [47] and 
may be a surrogate marker of a less effective host immune 
response. Also, fever in malaria is thought to be caused 
partly by TNF and other pyrogenic cytokines released as 
part of the human immune response to products of schi-
zont rupture [50, 51].
The relationship between PC1/2 and parasitaemia was 
different between the sensitive and resistant parasite pop-
ulations. In sensitive areas, high parasitaemia was associ-
ated with shorter PC1/2 largely because patients with low 
initial parasitaemias and rapid clearance are not included 
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in the analysis. In resistant populations with longer PC1/2, 
high parasitaemias were associated with slightly longer 
PC1/2 (by 5.2 % per tenfold increase).
The main limitation of this analysis is the heterogene-
ity in study designs and treatments which did not per-
mit a more detailed examination of treatment and dose 
effects, as they were confounded by the exclusion of 
patients with relatively low initial parasitaemias, differ-
ent partner drugs, and different timings and frequencies 
of sampling.
Conclusion
This pooled analysis showed that the main factor affect-
ing estimates of parasite clearance is the study design—
relatively low initial parasitaemia resulting in too few 
data points to estimate the clearance accurately, and too 
infrequent sampling. Additionally, in artemisinin-sensi-
tive parasite populations, PC1/2 is affected by artemisinin 
dose, patient age and the presence of fever as likely surro-
gates of acquired immunity. Therefore, it is important to 
consider these factors in early surveillance of changes in 
parasite sensitivity. This pooled analysis provides critical 
baseline information to monitor future evolution of PC1/2 
in malaria endemic countries.
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